From the LA County and University of Southern California General Hospital and Clinic (R.B.), Los Angeles; Kazan State Medical University (A.Y.), Russia; UCLA (J.E.), Los Angeles, CA; GRECC, VA Salt Lake, University of Utah (N.C.), Salt Lake City; and Stanford University (L.S.), Palo Alto, CA.
Neurol Neuroimmunol Neuroinflamm. 2021 Feb 15;8(2). doi: 10.1212/NXI.0000000000000961. Print 2021 Mar.
To present observations on administration of natalizumab to 18 patients with the comorbid MS and psoriasis, who represented a full subset of patients with such comorbidity within the patient records available.
A retrospective analysis of patient records was performed. Patient histories were gathered and included date of diagnosis of MS and psoriasis, MS disease-modifying therapies (DMTs), Expanded Disability Status Scale (EDSS), reason for DMT switch, and effects on MS and psoriasis status.
On initiation of natalizumab, all 18 patients had a complete cessation of MS disease activity (within 2-8 months) with significant patient-reported improvement of psoriasis (within 1-5 months). This improvement was independent of previous MS therapy and led to 15 of 18 patients needing no additional treatment for MS and psoriasis (remaining 3 patients continued to use topical treatments for psoriasis).
In this cohort of 18 patients with comorbid MS and psoriasis, beneficial results on both diseases were observed after initiation of therapy with natalizumab.
观察 18 例合并多发性硬化症（MS）和银屑病的患者接受那他珠单抗治疗的情况，这些患者代表了可获取的患者记录中存在这种合并症的所有患者子集。
对患者记录进行回顾性分析。收集患者病史，包括 MS 和银屑病的诊断日期、MS 疾病修正治疗（DMT）、扩展残疾状态量表（EDSS）、DMT 转换的原因，以及对 MS 和银屑病状况的影响。
在开始使用那他珠单抗时，所有 18 例患者的 MS 疾病活动均完全停止（2-8 个月内），且患者报告的银屑病显著改善（1-5 个月内）。这种改善与之前的 MS 治疗无关，导致 18 例患者中有 15 例无需再进行 MS 和银屑病的额外治疗（其余 3 例继续使用银屑病的局部治疗）。
在这组 18 例合并 MS 和银屑病的患者中，在开始那他珠单抗治疗后，两种疾病均观察到有益的效果。
